Canada has the opportunity to be an international leader in personalized medicine and needs to invest in this area for the health of Canadians, explains Program Co-chair Agnes V. Klein, MD, DRPH, Director, Center for Evaluation of Radiopharmaceuticals and Biotherapeutics, BGTD, HPFB, Health Canada.
Horsham, PA (Vocus) September 2, 2009
The Drug Information Association (DIA) will host Personalized Medicine: Biomarkers and Diagnostics in Drug Development, Regulatory Approval, and Access to Patients from October 15-16, 2009 in Toronto, Ontario, Canada.
Speakers from academia, industry, regulatory agencies and patient groups will discuss the needs and opportunities from their specific points of view and explore the scope, science and medical elements of personalized medicine that can be used as indicators of disease diagnosis, progression, treatment and prognosis and would allow for a better targeting of the right therapies for patients. Sessions will include:
- Personalized Medicine: Definition and Examples: Impact on Drug Development, Research and Development and Innovation
- What are the Biomarkers?
- What are the Diagnostics (Molecular, Genomics, Imaging, Point of Care, Immunology)?
- Regulatory Considerations
- Policy Considerations
- Translation to Clinical Delivery
- Prescriber and Patient Perspective
- View on the Future Value to Canadians and the Healthcare Systems and Next Steps
"Canada has the opportunity to be an international leader in personalized medicine and needs to invest in this area for the health of Canadians, explains Program Co-chair Agnes V. Klein, MD, DRPH, Director, Center for Evaluation of Radiopharmaceuticals and Biotherapeutics, BGTD, HPFB, Health Canada."
Click here to register.
Click here to view program for the upcoming 7th Canadian Annual Meeting to be held November 3-4, 2009 in Ottawa, Ontario, Canada.
About the Drug Information Association (DIA):
DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit http://www.diahome.org or call 215-442-6100.